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Abstract Epidemiological studies have shown an
increased occurrence of metabolic disorders such as insulin
resistance (IR) and steatosis in patients with hepatitis C
virus (HCV) infection. IR is believed to represent one of
the central clinical features of the ‘‘metabolic syndrome’’
and the major pathogenetic factor for type 2 diabetes
mellitus. In patients with chronic HCV hepatitis, IR may
have several dangerous consequences such as accelerated
progression of liver fibrosis, resistance to antiviral therapy
and development of hepatocellular carcinoma. According
to recent evidence, the global epidemic of metabolic dis-
orders related to incorrect diets will lead physicians to deal
with 1.2 billion patients with diabetes in the world in 2025.
Given the high prevalence of HCV infection in several
countries, metabolic manifestations will contribute to
increasing morbidity and mortality in patients with HCV
chronic infection in the near future. HCV treatment, shown
able to decrease both the occurrence of HCV-related IR
and diabetes, may reduce the risk of the associated
morbidities.
Keywords Chronic hepatitis C  Insulin resistance 
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Introduction
Hepatitis C virus (HCV) is a positive-strand RNA virus of
the Flaviviridae family, responsible for chronic hepatic
infection in 160 million people worldwide [1]. Infection
may resolve spontaneously in 15–40 % of cases [2], while
leading to chronic and progressive disease in the majority
of subjects. Cirrhosis and hepatocellular carcinoma (HCC)
represent the end-stage liver diseases associated with HCV
and are the first indications for liver transplantation in
western countries. Although morbidity and mortality
associated with HCV are mainly a consequence of HCV-
induced liver disease, co-factors associated with HCV
infection, including metabolic syndrome, play a relevant
additional role.
As shown in the recently published Global Burden dis-
eases risk assessment analysis [3], metabolic syndrome is
an increasing phenomenon currently associated with
increased mortality. It is reaching pandemic proportions
and is expected to increase in particular in East Asia, North
Africa and the Middle East, and Latin America. For these
reasons, the association between HCV chronic infection
and metabolic syndrome may assume dangerous propor-
tions and have devastating consequences in the near future.
Diabetes
After initial evidence suggesting that the occurrence of
type 2 diabetes mellitus (T2DM) in patients with HCV
infection was a consequence of impaired glucose metabo-
lism related to cirrhosis [4], large studies have been per-
formed in the general population and in large cohorts of
patients followed longitudinally. These studies showed that
diabetes is more frequent in patients with HCV infection
than in those with HBV, whatever the severity of liver
disease [5, 6]. In 2000, in about 10,000 subjects from the
NHANES III cohort, representative of the general adult
population in the USA, Metha evaluated the prevalence of
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T2DM in HCV versus non-HCV subjects according to
different age classes [5]. The overall prevalence of diabetes
in that cohort was 8.2 % and that of HCV 2.1 %. An
increase in the prevalence of diabetes was registered with
the increase in age with a peak of 30–35 % among HCV-
positive subjects aged 60–90. The adjusted odds risk of
diabetes in patients with HCV aged 40 or older was 3.77
(95 % CI 1.80–7.8) [5].
The most elegant study on the role of HCV in DM is a
further study published by Metha in 2003 [7]. This was a
longitudinal study on a cohort of more than 1,000 patients
followed for 9 years. The study showed that HCV precedes
the development of diabetes in patients with known pre-
disposing conditions such as older age, overweight and
male gender. These data support a temporal and causal
relationship between hepatitis C infection and diabetes and
highlight the promoting role of HCV in patients with other
risk factors.
The association between HCV and diabetes with liver
disease severity was explored by Hui et al. [8]. In patients
with HCV infection and low fibrosis stage (0 or 1), levels of
insulin resistance, C peptide and homeostatic model
assessment for insulin resistance (HOMA-IR) were signifi-
cantly higher as compared to matched healthy controls. This
concept was further expanded in a recent paper by Maucari
et al. [9], who demonstrated the same difference comparing
patients with HCV with matched HBV-infected subjects.
A further confirmation of an increased risk of diabetes in
patients with HCV infection was derived from studies
performed in selected groups of patients such as the
recipients of liver or kidney transplant. In these patients, an
increased incidence of ‘‘de novo’’ diabetes was registered
among HCV-infected as compared to HCV-negative
patients [10]. The first report by Knobler in 1998 on liver-
transplanted patients demonstrated a four- to eight-fold
increase in the occurrence of ‘‘de novo’’ diabetes in HCV-
positive patients [11]. Elevated HOMA-IR values and post-
transplant diabetes were associated with accelerated pro-
gression of fibrosis after transplant [12–14].
According to this evidence, in patients with HCV fec-
tion, the risk of insulin resistance and diabetes is doubled
per se. A recent meta-analysis combining the results of the
massive data on this topic, grouped by study design, con-
firmed that HCV plays a promoting role in diabetes [15].
Strikingly, Arase et al. [16] recently showed that HCV
treatment may decrease the annual incidence of diabetes in
HCV-infected patients, independently of other predispos-
ing factors. Once sustained virological response to antiviral
treatment has been achieved, T2DM may be prevented.
Aghemo et al. [17] confirmed these results, showing that
viral eradication after treatment is also able to reduce the
occurrence of insulin resistance significantly. Very
intriguing results were shown by a recent study
demonstrating that danoprevir, an HCV NS3 protease
inhibitor, when used as monotherapy, in parallel with a
reduction in viral load is able to reduce IR [18]. All these
data further support the direct relationship between HCV
and glucose metabolism.
Pathogenesis of HCV-induced insulin resistance
To explain the pathogenesis of HCV-induced insulin
resistance, both direct and indirect mechanisms have been
investigated. The direct mechanism hypothesizes a direct
interference between HCV core proteins and hepatocyte
intracellular insulin signaling. As first suggested by Aytug
et al. [19] in a landmark study conducted incubating with
insulin 42 liver biopsies of non-obese, non-diabetic HCV-
positive patients matched with those of 10 non-HCV
patients, HCV core protein inhibited the insulin signaling.
HCV interferes with serine phosphorylation of insulin
receptor-1 (IRS-1) and induces impairment of the down-
stream tyrosin kinase activity (AKT) signaling pathway
and impaired cellular response to insulin. Several studies
analyzed the mechanism of HCV-induced IR. In parallel
with evidence gathered in vivo, Shintani et al. [20] showed
in a transgenic mouse model that insulin fails to suppress
hepatic glucose production in animals overexpressing core
protein and that IR precedes the occurrence of steatosis.
Recent studies have indicated that the suppressor of the
cytokine signaling (SOCS) family that suppresses the
insulin signaling cascade through proteosomal degradation
and ubiquination of insulin receptor substrate 1 and 2 (IRS)
has a key role in IR development in HCV infection [21].
Moreover, Vanni et al. [22] reported an increase in intra-
hepatic SOCS-3 mRNA expression in subjects with IR.
SOCS-3 also inhibits the interferon-induced Janus kinase-
signal transducer and suppresses the expression of antiviral
proteins, including 2,5-OAS and myxovirus resistance A
[23–27]. Increased SOCS-3 expression is reported not only
in obese subjects, but also in HCV itself. Finally, the
hepatic expression of SOCS-3 predicts the outcome of
antiviral therapy, which is significantly increased in non-
responder patients as compared with responders [28–31].
At variance with the initial hypothesis that correlated
different pathogenetic mechanisms with the different HCV
genotypes, currently it seems that SOCS mechanisms are
active across all the different genotypes.
More recently, using the euglycemic clamp in combi-
nation with the infusion of tracers and indirect calorimetry,
it has been shown that an infected liver secretes cytokines
or soluble factors able to target distant organs such as
muscle and adipose tissue. This evidence supports the
existence of peripheral insulin resistance in HCV infection
[32].
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HCV, fatty liver and insulin resistance
Hepatic steatosis is another frequent disturbance of lipid
metabolism in patients with hepatitis C. Steatosis has been
viewed as a characteristic feature of chronic HCV-infected
liver, but whether the steatosis is directly related to the
presence of HCV or it results from host-related factors
remains uncertain. Different pathogenetic mechanisms
have been postulated to explain steatosis in patients with
HCV infection [33–36]. Moreover, controversial data
concerning the relationship between hepatic steatosis and
IR exist. Most accredited evidence suggests that HCV itself
induces IR development and that steatosis is a consequence
of IT. Glucose activates the nuclear transcription factor
carabohydrate response. Element-binding protein (ChRE-
BP), by upregulating the conversion of glucose into pyru-
vate, increases the expression of L-pyruvate. ChREBP
increases transcription of the lipogenic enzyme acetyl-CoA
carboxylase and fatty acid synthase genes. [37].
In patients with HCV-3, many studies support the
hypothesis that steatosis can be directly driven by the virus.
Indeed, a direct relationship between HCV replication and
steatosis has been observed [38]. To confirm this cause-
effect relationship, two concepts have been described: first,
the disappearance of steatosis once HCV has been eradi-
cated by treatment [39]; second, the correlation between
the severity of steatosis and the level of HCV RNA [39,
40]. Steatosis observed in HCV-3 is believed to be of viral
origin, although there are Japanese studies on HCV 1
showing an association between substitution of HCV core
amino acid 70 and hepatic steatosis [41, 42].
As shown by Serfaty et al. [43] in mice, impaired
lipoprotein secretion may be an independent mechanism
explaining lipid accumulation in HCV infection. In this
experimental model, HCV core protein interferes with
VLDL assembly and secretion by targeting the microsomal
triglyceride transfer protein (MTP). MTP plays a limiting
role in VLDL assembly, and its inhibition leads to the
accumulation of trygliceride alternatively uploaded onto
VLDL and secreted. Other studies propose that the fatty
acid oxidative pathway is altered. Yasui and others [44, 45]
reported that the levels of mRNA and PPARa protein, a
nuclear receptor associated with genes implicated in fatty
acid oxidative processes, are less expressed in HCV
patients with than in those without steatosis. Finally, very
recently, the experimental evidence gathered using the
euglycemic clamp showed that NEFAs are not increased in
patients with HCV as compared to non-HCV infected
controls and suggests the existence of different pathoge-
netic mechanisms [32].
In patients with HCV non-3 genotype infection, fatty
liver seems to be related to an increased body mass index
[46]. As shown by Fartoux et al. [47], using the HOMA-IR
in a cohort of 141 patients, only 28 were infected with
genotype 3, and the median HOMA-IR value was signifi-
cantly higher in HCV-1 patients with steatosis than in those
with HCV-3. This evidence supports different mechanisms
for steatosis according to HCV genotypes and may also
explain the different mechanisms underlying the effects of
steatosis on fibrosis. Ultimately, in non HCV-3 genotypes,
the effect of steatosis on liver fibrosis seems to depend on
the pathogenesis of fat accumulation.
Recent findings on the role of genetic variants associated
with different responses to interferon-based treatment, the
single-nucleotide polymorphisms near the IL28B gene,
shed further light on the pathogenetic mechanism of stea-
tosis in HCV infection, suggesting that different genetic
backgrounds may be conditions for the development of
steatosis regardless of the genotype in HCV-infected sub-
jects. Indeed, in liver biopsies of patients with HCV 1
infection, it has been shown that steatosis is less repre-
sented in carriers of the IL28B CC genotype, which pre-
dicts a favorable response to interferon therapy [48]. This
evidence confirms previous data demonstrating a reduction
in serum trygliceride levels and an increase in serum LDL
cholesterol levels in patients with IL28B CC [49]. More-
over, an association between CC and lower gamma-GTP
levels has also been shown. Because gamma-GTP tends to
be elevated in patients with steatosis, these results suggest
that the lower levels of this liver enzyme may be consid-
ered a consequence of a lower degree of steatosis associ-
ated with CC. The lower levels of lipids in these patients
seem to be due to a more efficient export of lipids from
cells in carriers of IL28B CC [50].
Clinical consequences of IR
Fibrosis severity and progression
According to the reported evidence, the interplay between
HCV and metabolic disorders induces liver disease com-
plications; first of all, it accelerates the progression of
fibrosis. A close relationship between IR and liver fibrosis
has been shown in many studies. Hui et al. [8] reported
that, in 260 patients with chronic hepatitis C, the HOMA-
IR score, but not steatosis, was associated with the severity
of fibrosis and accelerated the rate of progression. There-
fore, regardless of the viral genotype and severity of liver
damage, serum insulin concentrations and HOMA-IR
index scores increase with the severity of hepatic fibrosis.
Petta et al. found that in HCV genotype 1 patients, HOMA-
IR scores [2.7 and platelet levels\200 9 103/ll were the
diagnostic criteria for severe fibrosis (F3 and F4) [51]. The
association between IR and hepatic fibrosis exists inde-
pendently of the exclusion of cirrhotic patients from the
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analysis or of the adjustment for other factors associated
with fibrosis, including steatosis [52]. This suggests that
insulin is a driving force behind accelerated fibrosis pro-
gression in patients chronically infected with HCV [53].
Hyperinsulinemia and hyperglycemia directly stimulate
hepatic stellate cells, leading to activation of connective
tissue growth factor and subsequent accumulation of
extracellular matrix [54, 55]. In addition, leptin and TNF-a
could be the molecules responsible for accelerated fibrosis.
Patients diagnosed with IR frequently show hyperleptin-
emia and increased serum TNF-a levels; both of these are
also able to activate hepatic stellate cells, leading to
increased fibrogenesis [56, 57].
The hypothesis of an association between steatosis and
fibrosis progression in HCV-infected patients needs to be
confirmed. Indeed, while several studies claimed that there
is an association between steatosis and fibrosis progression,
very few evaluated the association with a proper method-
ological approach. Thus, only longitudinal studies investi-
gating paired biopsies might guarantee sound results on
this association. Of interest, in the Maid study, a large
multicenter cohort study involving HCV patients infected
with multiple genotypes from different countries around
the world, it was demonstrated that while the main pre-
dictor of fibrosis in patients with genotype 1 is the presence
of diabetes, in HCV-3 a higher grade of inflammatory
activity is independently associated with fibrosis progres-
sion [58].
HCC development
In patients with diabetes, HCV is an independent factor for
the development of HCC, even after adjusting for the
confounding variables of age and gender [59, 60]. It is well
recognized that in males a HOMA-IR score [3 is an
independent predictor of HCC [61, 62]. The molecular
mechanisms underlying the link between IR and HCC
remain unclear and include the mitogenic role of insulin
and its stimulating property on cell proliferation [63].
Additional hypotheses are based on the binding of insulin
with insulin-like growth factor (IGF)-1 receptor, resulting
in the activation of tyrosine kinase and a cascade of
downstream intracellular responses [63]. The question is
now whether the coexistence of HCV increases the risk of
cancer in patients with metabolic syndrome. Strikingly,
insulin resistance and obesity are associated with a higher
risk of adenocarcinoma, including colon cancer [63]. The
long duration of chronic HCV diseases hampers designing
effective studies. Therefore, it is not surprising that a
number of small studies evaluating the association among
HCV, diabetes and HCC reached contrasting results on this
debated aspect. In paired biopsies of patients with HCV
who did or did not develop cancer, Kumar et al. [64] failed
to show an association with diabetes. In contrast, a study
performed by Pekow [65] on explanted livers of patients
with cancer demonstrated an association between a more
severe liver steatosis and the presence of cancer. A pro-
moting role of HCV has been shown in a large European
multicenter study conducted by Veldt et al. [66]. In this
study, the coexistence of diabetes increased the frequency
of liver cancer in comparison to HCV infection alone [66].
In contrast, in a study on 82,000 veterans with HCV
infection and a comparable number of non-HCV-infected
patients, despite a lower frequency of hypercholesterol-
emia, hypertrygliceridemia, hyperlypemia and hyperten-
sion in HCV-infected patients, a significant increase in the
risk of liver cancer in the presence of a higher degree of
steatosis was demonstrated [59].
Atherosclerosis development
A further question on the interactions between HCV and
metabolic disorders is related to the possible increased risk
of cardiovascular morbidity and mortality in patients with
chronic hepatitis C. The results so far accumulated on this
topic are contradictory. In a large European survey, the risk
of arterial damage observed in patients with HBV was
comparable to that of patients with HCV infection [67].
However, recently, exploring surrogate markers of car-
diovascular mortality, evidence of intima-media thickness
(IMT) and carotid plaques was investigated [68]. In the
Reveal HCV cohort, a 1.5 risk of cardiovascular-related
deaths was registered in Taiwan [69]. The association was
significantly higher in patients with active HCV RNA
replication [64]. Petta et al. [70] evaluated the prevalence
of carotid atherosclerosis compared with a control popu-
lation in order to assess the potential association among
atherosclerosis, host and viral factors, and liver histological
features. Out of 174 consecutive G1 CHC patients, 73
(41.9 %) showed carotid plaques at a rate significantly
higher than that of control subjects (22.9 %) (p \ 0.001).
Similarly, HCV-1 chronic hepatitis C patients had a greater
IMT compared with control patients (1.04 ± 0.21 vs.
0.90 ± 0.16; p \ 0.001). Multivariate logistic regression
analysis showed that older age [odds ratio (OR) 1.047,
95 % confidence interval (CI): 1.014–1.082, p = 0.005]
and severe hepatic fibrosis (OR 2.177, 95 %
CI:1.043–4.542, p = 0.03) were independently linked to
the presence of carotid plaques.
Reduced response to interferon treatment
The treatment of metabolic disorders in HCV-infected
patients coincides with the treatment of HCV. However,
among the clinical consequences of HCV-induced IR, there
is an impaired response to antiviral treatment [71].
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Although not unanimously accepted, rates of response to
antiviral treatment, including pegylated interferon and
ribavirin, are inversely associated with HOMA-IR index
scores [72]. An increased HOMA-IR index score is asso-
ciated with reductions in 24-h virological response, early
virological response (EVR) and sustained virological
response (SVR) to antiviral therapy [73]. The relevance of
IR in antiviral therapy based on the combination of pegy-
lated interferon and ribavirin has been reported, regardless
of the HCV genotype [74, 75].
An increase of HCV RNA levels and reduced rates of
SVR, irrespectively of other response predictors, have
indeed been registered in HCV-infected patients.
Several studies evaluated the negative effect of IR on
SVR. The first evidence was reported by Romero-Gomez
et al. [76] in patients with HCV-1 infection. A French
meta-analysis recently showed that the rate of SVR is
significantly reduced by the severity of IR in patients with
HCV infection overall and in patients with genotype 1 in
particular [77]. However, the study showed an inverse
correlation between the severity of IR and SVR in both
HCV patients overall and patients with HCV-1 in particular
[77]. The impact of HOMA-IR in patients with genotype 2
and 3, in case of dual treatment with pegylated interferon
and ribavirin, was recently explored by Poustchi et al. [78].
In these patients, a six-fold risk of non-response in case of a
HOMA-IR value higher than 2 was observed.
Many authors have been trying to increase insulin sen-
sitivity with the aim of increasing SVR. In particular,
antidiabetic drugs such as metformin and thiazolidinedi-
ones have been used to improve insulin sensitivity. In a
multicenter study, treatment non-responders were re-trea-
ted with pegylated interferon-a, ribavirin and pioglitazone.
An early termination of this study was required as none of
the patients showed a virological response at week 12
despite the improvement in insulin sensitivity [79].
Another analysis in naı¨ve non-diabetic patients who
received a lead-in regimen of pioglitazone monotherapy for
4 weeks, followed by pioglitazone added to standard
therapy with pegylated interferon-a and ribavirin, revealed
that, despite an increase in rapid virologic response, no
significant effect on SVR can be appreciated. [80]. Treat-
ment with metformin or thiazolidinediones, in addition to
antiviral therapy, will probably be less important in the
future, when more potent antivirals, such as the combina-
tion of different direct inhibitors of HCV enzymes, will be
used in clinical practice. Currently, the uselessness of
insulin sensitizers to reduce the severity of IR before
starting an antiviral treatment plays against the idea that
insulin resistance per se reduces SVR.
According to the knowledge accumulated so far, the
only way to obtain an increase in the rates of SVR in these
patients may be to advise weight loss before starting
antiviral treatment [81]. As shown in patients without
concomitant viral hepatic infections, only exercise ensures
both fat deposit and liver enzyme decreases.
IR can be influenced by lifestyle changes. It is known
that weight loss can improve different clinical features of
metabolic syndrome, including insulin sensitivity, irre-
spectively of the pathogenesis. Moreover, a study on 19
subjects showed that weight loss may also improve fibrosis
in CHC patients [82]. Aerobic exercise improves HOMA-
IR values and decreases body fat in patients with chronic
hepatitis C.
As anticipated, with the use of triple combination
treatment including protease inhibitors, the role of IR
showed a minor impact. Strikingly, danoprevir response is
not reduced by insulin resistance status [83]. As demon-
strated by Serfaty et al. [84] in naı¨ve HCV-1 patients
receiving triple treatment with pegylated interferon, riba-
virin and telaprevir, HOMA-IR values were not predictive
of virological response, while sustained virological
response appeared to be associated with improved HOMA-
IR scores. These results suggest that metabolic factors and
insulin resistance do not have a significant effect on tela-
previr-based treatment efficacy.
These data led us to expect that a pre-treatment evalu-
ation of HOMA-IR, encouraged by the previously reported
meta-analysis results, may be less relevant in the future
workup of patients undergoing triple treatment regimens.
In our experience, higher body mass index and severe
liver damage have been associated with higher rates of
relapse in patients with HCV-2 and 3 receiving short
treatments [85]. Therefore, lifestyle changes are urgently
recommended in patients such as those with genotype 2
dealing with dual treatment in the immediate future. The
forthcoming analyses of data obtained in the Fission study
with all oral interferon-free regimens combining sofosbuvir
with ribavirin in patients infected with HCV-2 and 3 may
shed further light on the future role of both HOMA-IR and
dieting in patients infected with these genotypes.
Conclusions
Hepatitis C is associated with IR, which in turn contributes
to the progression of fibrosis, the development of HCC and
perhaps an increased risk of cardiovascular diseases. IR
may lead to the development of diabetes in subjects with
HCV infection and predisposing factors.
Treatment of HCV may reduce the burden of metabolic
disorders. In patients infected with HCV-1, the use of more
efficient therapies than the combination of pegylated
interferon and ribavirin will decrease the need for a pre-
treatment HOMA-IR assessment in order to define a correct
prediction of SVR. In contrast, in patients with HCV-2 and
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3 still receiving the combination of pegylated interferon
and ribavirin as standard of care treatment, a correct pre-
treatment assessment of the risk of diabetes together with
advice on exercising to reduce body weight might reduce
the risk of relapse.
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